Multi-omics approach for identification of molecular alterations of QiShenYiQi dripping pills in heart failure with preserved ejection fraction

被引:6
|
作者
Huang, Yuting [1 ,2 ]
Zhang, Kai [1 ,4 ,5 ]
Wang, Xiao [1 ,4 ]
Guo, Kaimin [3 ]
Li, Xiaoqiang [3 ]
Chen, Feng [1 ,4 ]
Du, Ruijiao [4 ]
Li, Sheng [1 ,4 ]
Li, Lan [4 ]
Yang, Zhihui [1 ,4 ]
Zhuo, Danping [1 ,4 ]
Wang, Bingkai [1 ,4 ]
Wang, Wenjia [3 ]
Hu, Yunhui [3 ]
Jiang, Miaomiao [4 ]
Fan, Guanwei [1 ,4 ,5 ]
机构
[1] Tianjin Univ Tradit Chinese Med, Natl Clin Res Ctr Chinese Med Acupuncture & Moxibu, Teaching Hosp 1, Tianjin 300193, Peoples R China
[2] Gannan Med Univ, Affiliated Hosp 1, Key Lab Prevent & Treatment Cardiovasc & Cerebrova, Minist Educ, Ganzhou 341000, Peoples R China
[3] Cloudphar Pharmaceut Co Ltd, Shenzhen 518000, Peoples R China
[4] Tianjin Univ Tradit Chinese Med, State Key Lab Component Based Chinese Med, Tianjin 301617, Peoples R China
[5] Tianjin Key Lab Translat Res TCM Prescript & Syndr, Tianjin 300193, Peoples R China
基金
中国国家自然科学基金;
关键词
Heart failure with preserved ejection fraction; Herbal preparation; Multi-omics analysis; Therapeutic target; PKG; CHINESE MEDICINE; DYSFUNCTION; MECHANISMS; PARADIGM;
D O I
10.1016/j.jep.2023.116673
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharmacological relevance: Traditional Chinese medicine theory believes that qi deficiency and blood stasis are the key pathogenesis of heart failure with preserved ejection fraction (HFpEF). As a representative prescription for replenishing qi and activating blood, QiShenYiQi dripping pills (QSYQ) has been used for treating heart diseases. However, the pharmacological mechanism of QSYQ in improving HFpEF is not well understood.Aim of the study: The objective of the study is to investigate the cardioprotective effect and mechanism of QSYQ in HFpEF using the phenotypic dataset of HFpEF. Materials and methods: HFpEF mouse models established by feeding mice combined high-fat diet and N & omega;-nitro-Larginine methyl ester drinking water were treated with QSYQ. To reveal causal genes, we performed a multiomics study, including integrative analysis of transcriptomics, proteomics, and metabolomics data. Moreover, adeno-associated virus (AAV)-based PKG inhibition confirmed that QSYQ mediated myocardial remodeling through PKG.Results: Computational systems pharmacological analysis based on human transcriptome data for HFpEF showed that QSYQ could potentially treat HFpEF through multiple signaling pathways. Subsequently, integrative analysis of transcriptome and proteome showed alterations in gene expression in HFpEF. QSYQ regulated genes involved in inflammation, energy metabolism, myocardial hypertrophy, myocardial fibrosis, and cGMP-PKG signaling pathway, confirming its function in the pathogenesis of HFpEF. Metabolomics analysis revealed fatty acid metabolism as the main mechanism by which QSYQ regulates HFpEF myocardial energy metabolism. Importantly, we found that the myocardial protective effect of QSYQ on HFpEF mice was attenuated after RNA interference-mediated knock-down of myocardial PKG.Conclusion: This study provides mechanistic insights into the pathogenesis of HFpEF and molecular mechanisms of QSYQ in HFpEF. We also identified the regulatory role of PKG in myocardial stiffness, making it an ideal therapeutic target for myocardial remodeling.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Effect of Qishen Yiqi dripping pills on the classification of ejection fraction in patients with ischaemic heart failure: A prospective cohort study
    Zhou, Zhou
    Wang, Shuai
    Fan, Zixuan
    Zhang, Zeyu
    Zhang, Xuan
    Zhao, Zhiqiang
    Wang, Xianliang
    Mao, Jingyuan
    PHYTOMEDICINE, 2025, 139
  • [32] Sympathetic and baroreflex alterations in congestive heart failure with preserved, midrange and reduced ejection fraction
    Seravalle, Gino
    Quarti-Trevano, Fosca
    Dell'Oro, Raffaella
    Gronda, Edoardo
    Spaziani, Domenico
    Facchetti, Rita
    Cuspidi, Cesare
    Mancia, Giuseppe
    Grassi, Guido
    JOURNAL OF HYPERTENSION, 2019, 37 (02) : 443 - 448
  • [33] Alterations in the gut microbiota composition in the obesity phenotype of heart failure with preserved ejection fraction
    Rokach, Y.
    Abedat, S.
    Nachman, D.
    Dana, S.
    Qadan, A.
    Beeri, R.
    Amir, O.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2955 - 2955
  • [34] Myocardial Strain for Identification of β-Blocker Responders in Heart Failure with Preserved Ejection Fraction
    Park, Jin Joo
    Choi, Hong-Mi
    Hwang, In-Chang
    Park, Jun-Bean
    Park, Jae-Hyeong
    Cho, Goo-Yeong
    JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY, 2019, 32 (11) : 1462 - +
  • [35] Identification and validation of circulating microRNAs as biomarkers for heart failure with preserved ejection fraction
    Zhang, L.
    Yang, Y.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [36] Publisher Correction: Cellular and molecular pathobiology of heart failure with preserved ejection fraction
    Sumita Mishra
    David A. Kass
    Nature Reviews Cardiology, 2021, 18 : 735 - 735
  • [37] Heart failure with preserved ejection fraction in the elderly: pathophysiology, diagnostic and therapeutic approach
    Duque, Ernesto Ruiz
    Briasoulis, Alexandros
    Alvarez, Paulino A.
    JOURNAL OF GERIATRIC CARDIOLOGY, 2019, 16 (05) : 421 - 428
  • [38] Heart failure with preserved ejection fraction in the elderly: pathophysiology, diagnostic and therapeutic approach
    Ernesto Ruiz Duque
    Alexandros Briasoulis
    Paulino A Alvarez
    Journal of Geriatric Cardiology, 2019, 16 (05) : 421 - 428
  • [39] A network medicine approach to study comorbidities in heart failure with preserved ejection fraction
    Jan D. Lanzer
    Alberto Valdeolivas
    Mark Pepin
    Hauke Hund
    Johannes Backs
    Norbert Frey
    Hans-Christoph Friederich
    Jobst-Hendrik Schultz
    Julio Saez-Rodriguez
    Rebecca T. Levinson
    BMC Medicine, 21
  • [40] Epidemiology, Diagnosis, Pathophysiology, and Initial Approach to Heart Failure with Preserved Ejection Fraction
    Anderson, Theresa
    Hummel, Scott L.
    Konerman, Matthew C.
    CARDIOLOGY CLINICS, 2022, 40 (04) : 397 - 413